La reunión anual de la American Society of Clinical Oncology (ASCO) se está llevando a cabo del 3 al 7 de junio, y estas son algunas de las investigaciones destacadas que se presentarán hoy. Los estudios de hoy analizan la adición de nimotuzumab a la quimioterapia para tratar el cáncer pancreático con el gen KRAS en estado natural y la adición de ibrutinib a la atención estándar para adultos mayores con linfoma de células del manto. Read More
Blog
June 3, 2022 Greg Guthrie, ASCO staff
June 3, 2022 Greg Guthrie, ASCO staff
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma. Read More
June 2, 2022 Jyoti Patel, MD, FASCO
In this month’s “From the Editor in Chief” column, Dr. Jyoti Patel discusses the return of the American Society of Clinical Oncology (ASCO) Annual Meeting in person and online, and why bringing oncology professionals, researchers, advocates, and people with cancer back together is so important for cancer care. Read More
May 31, 2022 ASCO Staff
For people at high risk of developing skin cancer, doctors may recommend screening. Learn what to expect during a skin cancer screening and everyday ways to prevent skin cancer. Read More
May 27, 2022 Brielle Gregory Collins, ASCO staff
In this podcast, Dr. Jeffrey Meyerhardt and Dr. Scott Tagawa discuss clinical practice guidelines, including what they are, how they’re developed, and how they can impact care for people with cancer. Read More
